Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $9.00 at Citigroup

Sarepta Therapeutics (NASDAQ:SRPT) had its target price upped by Citigroup from $8.00 to $9.00 in a report issued on Tuesday,Benzinga reports. Citigroup currently has a sell rating on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on SRPT. Wedbush reduced their target price on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Barclays began coverage on Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price target for the company. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a report on Monday, March 2nd. Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and an average target price of $31.96.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $17.66 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock has a market capitalization of $1.85 billion, a PE ratio of -2.09, a P/E/G ratio of 0.26 and a beta of 0.42. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $103.32. The company has a fifty day moving average of $19.69 and a two-hundred day moving average of $20.03.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. During the same quarter last year, the business earned $1.90 EPS. The firm’s revenue for the quarter was down 32.7% compared to the same quarter last year. As a group, research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer owned 193,300 shares in the company, valued at approximately $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $25,000. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics during the third quarter worth $25,000. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares in the last quarter. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics in the third quarter valued at about $33,000. Finally, Allworth Financial LP raised its holdings in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.